Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Diagnostics » Molecular Diagnostics » Guardant360 Results in Alpelisib Trial Suggest Liquid Biopsy May Help Better Capture Non-Responders

Guardant360 Results in Alpelisib Trial Suggest Liquid Biopsy May Help Better Capture Non-Responders

Apr 15, 2020
|
Molika Ashford
Premium

NEW YORK – Data from a trial of the PIK3CA inhibitor alpelisib (Novartis' Piqray) has provided new evidence that liquid biopsy testing could help oncologists better identify patients likely to respond to the drug by picking up resistance mutations that might otherwise be missed due to tissue heterogeneity.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
14
Featured Webinar

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct
15
Featured Webinar

A Comparison of cfDNA Approaches to Guide Targeted Therapy in NSCLC

Sponsored by
Agena Bioscience

In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.

Oct
20
Featured Webinar

Crystal Digital PCR for Accurate Chimerism Monitoring after Stem Cell Transplantation

Sponsored by
Stilla

This webinar will discuss a new method that relies on Crystal digital PCR from Stilla Technologies to monitor chimerism in patients after stem cell transplantation, which is a key part of surveillance for impending clinical relapse.

What's Popular?

In Cancer

  1. Angle Files De Novo FDA Submission for CTC Collection Device in Breast Cancer

  2. Exact Sciences Stock Soars on New Data Around Pan-Cancer Liquid Biopsy Test

  3. Natera Cancer Liquid Biopsy Test Coverage to Expand Under New Draft LCD

  4. Ionpath Expanding Sales Force, Investing in Informatics Tools Development

    Premium

  5. Palmetto Expands Coverage for Decipher Biosciences Prostate Cancer Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.